20 September 2015
Pet Diabetes Month back on practice calendar this November
Free pet diabetes testing kits to be made available for cat and dog owners
MSD Animal Health, the manufacturer of Caninsulin®, has confirmed that Pet Diabetes Month will take place in November for the seventh year running. The event is becoming an established staple of the veterinary marketing calendar.
This year as well as raising awareness of pet diabetes, the campaign will focus on detection of the condition through testing of cat and dog urine samples. Vet practices across the country will be working alongside MSD Animal Health to help raise awareness of the risks of diabetes mellitus as well as show-casing the campaign’s Pet Diabetes Month leaflet packs which contain a free diabetes ‘dipstick’ test kit, within waiting room displays throughout November.
A new campaign website at www.mypetonline.co.uk/petdiabetesmonth along with campaign literature will highlight that unfortunately, like people, pets can develop diabetes mellitus and the problem is growing (1) with as many as 1 in 200 pets suffering from the condition (2). But it will also spell out that with veterinary support and treatment, it is possible to manage the condition.
MSD Animal Health is supporting Pet Diabetes Month and Zorica Agbaba, the Product Manager responsible for the company’s insulin brand and diabetic support services says: - more - “While caring for a pet with diabetes requires dedication, most owners who have tackled the condition have a positive experience, with 70% of dog owners and 90% of cat owners saying that having treated their own pet they would ‘without a doubt’ recommend that others in the same position go ahead and treat.3,4
“Unfortunately, diabetes is an under-diagnosed disease and we know there are pets out there suffering in silence from the condition. By providing test kits during Pet Diabetes Month vet practices are giving owners the opportunity to check their cats and dogs and protect their pets’ health. “It is important to communicate to pet owners that today a positive diagnosis of diabetes does not spell disaster as with the right care, veterinary medicine and diet, dogs and cats with the disease can live long and happy lives.
“Today, even owners who are anxious about using needles and syringes no longer need to worry about managing their diabetic pets’ medication. Caninsulin® VetPen® makes giving insulin to their cats and dogs so much simpler for pet owners and helps ensure the accurate dose of insulin is given. With the support of veterinary practices, controlling diabetes is something that pet owners can feel much more relaxed about.”
Further details can be found at www.mypetonline.co.uk/petdiabetesmonth. The website will also be a central source of information about what’s going on during the campaign, tips on diabetes detection and prevention, plus lots of fun activities to get the attention of pet owners of all ages. Practices can order practice waiting room posters and leaflets containing free diabetes testing kits now by calling 01908 685 685 and selecting option 3 for Customer services or emailing firstname.lastname@example.org.
Use medicines responsibly: Caninsulin® is an aqueous suspension of insulin containing 40 i.u./ml highly purified porcine insulin. For further information please refer to the Caninsulin summary of product characteristics. Legal category POM-V. MSD Animal Health, Walton Manor, Walton, Milton Keynes, MK7 7AJ. For further information please contact your MSD account manager or Technical Product Support• Tel: 01908 685685 • Fax: 01908 685606
1. Diabetes global market research – July 2013, UK – MSD
2. Panciera DL, Thomas CB, Eicker SW, Atkins CE. Epizootiologic patterns of diabetes mellitus in cats: 333 cases (1980–1986). J Am Vet Med Assoc.1990;197(11):1504–1508.
3. Niessen S.J.M., Powney S., Guitian J., Niessen A. P.M., Pion P.D., Shaw J.A,M, and Church D.B., Evaluation of a quality-of-Life tool for dogs with diabetes mellitus, J Vet Intern Med 2012;26:953–961
4. Niessen S.J.M., Powney S., Guitian J., Niessen A. P.M., Pion P.D., Shaw J.A,M, and Church D.B., Evaluation of a quality-of-life tool for cats with diabetes mellitus, J Vet Intern Med 2010;24:1098–1105
About MSD Animal Health
Today's MSD is a global healthcare leader working to help the world be well. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, NJ, USA., is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn.
MSD forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of MSD’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; MSD’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of MSD’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
MSD undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in MSD’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).